[1] RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine
tumors. Retrieved February 12, 2024 from https://www.oranomed.com/en/resources/news/2024/radiomedix-and-orano-med-receive-fda-breakthrough-therapy-designation-for-alphamedixtm-in-gastroenteropancreatic-neuroendocrine-tumors